Skip to content
Home/Companies/Biotech/Prexton Therapeutics

Prexton Therapeutics

Biotech·CH·Exited 2018·Held 1yr
Entry
2017
Hold
1yr
Exit
2018

Who owns Prexton Therapeutics?

Prexton Therapeutics was owned by Ysios Capital Partners through Ysios BioFund II Innvierte (2016 vintage) from 2017 to 2018, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-03

Ysios Capital Partners
Investor
Ysios Capital Partners
Ysios BioFund II Innvierte · 2016 · Life Sciences VC

Key facts

HQCH
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2018

More from Ysios BioFund II Innvierte

Other portfolio companies in the same fund.

Anaconda Biomed
Anaconda Biomed
Active
MedTechES· 2017
Babyscripts
Babyscripts
Active
HealthTechUS· 2017
Vivet Therapeutics
Vivet Therapeutics
Active
BiotechFR· 2017
Xeltis
Xeltis
Active
MedTechNL· 2017
AELIX Therapeutics
AELIX Therapeutics
Active
BiotechES· 2016
CorWave
CorWave
Active
MedTechFR· 2016

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Prexton Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Prexton Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue